GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel
Atlanta, GA, December 21, 2007 --(PR.com)-- GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta-based biotechnology company developing HIV-1/AIDS vaccines, announced today that it has retained Financial Relations Board (FRB), as its Investor and Public Relations agency of record.
“GeoVax’s promising HIV-1/AIDS vaccine human trial results need to be conveyed to those inflicted or threatened by the catastrophic AIDS pandemic,” stated Kathy Waller, co-president of FRB.
GeoVax selected FRB to deliver its very important message to those interested in the potential “control” of AIDS through administration of GeoVax vaccines which are currently in their 5th successful human trial. Many individuals throughout the world were greatly concerned by recent disappointing human trial failures of other key HIV/AIDS vaccine developers that utilized vaccine technologies quite different than those of GeoVax. FRB’s task will be to raise awareness of those significant differences. The media and investor information program as well as progress reports on GeoVax current and upcoming human trials will be conveyed on a regular basis. Media for the campaign may include print, television, radio and online information.
“We wanted to engage a firm that could effectively present the GeoVax story to current and prospective shareholders and to the media, while helping to educate the world about the crucial role that innovative vaccine technologies play in the fight against the global AIDS epidemic,” said Dr. Harriet Robinson, GeoVax co-founder/Chief Scientist.
“We look forward to being part of a team that will highlight GeoVax’s work in the frontline battle against HIV,” said FRB’s Kathy Waller. “FRB’s broad expertise in the biotech and healthcare industries will effectively convey the company’s vaccine development successes both to The Street and media communities.”
About GeoVax Labs, Inc. [www.geovax.com]
GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is covered by 20 issued or filed patent applications. GeoVax HIV/AIDS vaccines are designed to prevent development of Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, by vaccinating individuals prior to infection with the AIDS virus. In addition, GeoVax AIDS vaccines may be effective as therapeutics (treatment of people infected with AIDS virus). Studies evaluating these vaccines in already HIV/AIDS infected individuals are being planned.
GeoVax DNA and Recombinant MVA HIV/AIDS vaccines:
- Use DNA vaccines to “prime” immune responses and MVA vaccines to “boost” immune responses against the AIDS virus
- Express more than 50% of AIDS virus components in vaccinees and can not cause AIDS
- Protected 22 of 23 (96%) non-human primates against development of AIDS for over 3½ years
- Are manufactured & tested under GMP/GLP – EMEA (EU) and FDA guidelines
- Satisfactorily completed 2 earlier DNA & DNA/MVA -- HIV/AIDS vaccine Phase 1 human trials
- Are currently being tested in 3 Human Trials. One started in 2006, two in summer 2007
- Have been demonstrated safe to date in human trials
- Are demonstrating positive immune responses against HIV in the majority of vaccine recipients
- Are in planning stage for larger Phase 2 human trial in 2008
About Financial Relations Board
For more than 40 years, the Financial Relations Board has been one of the nation’s leaders for investor relations and financial communications. The firm offers a full array of services, including deep expertise in corporate positioning and communication, investment community targeting (market intelligence), financial media relations, shareholder management services, valuation analysis, and the company’s industry-leading Strategy Consulting Group. Financial Relations Board works alongside companies of all sizes, from established Fortune 100 brands to mid-size and micro-cap companies, pre-IPOs and the newly public. Headquartered in Chicago, the firm has full-service offices in New York, Los Angeles, San Francisco and Washington, D.C. Financial Relations Board is part of the Interpublic Group of Companies (NYSE: IPG). For more information on Financial Relations Board, visit www.frbir.com
Safe Harbor Statement: All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions on the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. Certain matters discussed in this news release are forward-looking statements involving certain risks and uncertainties including, without limitations, risks detailed in the Company’s Securities and Exchange Commission filings and reports.
###
“GeoVax’s promising HIV-1/AIDS vaccine human trial results need to be conveyed to those inflicted or threatened by the catastrophic AIDS pandemic,” stated Kathy Waller, co-president of FRB.
GeoVax selected FRB to deliver its very important message to those interested in the potential “control” of AIDS through administration of GeoVax vaccines which are currently in their 5th successful human trial. Many individuals throughout the world were greatly concerned by recent disappointing human trial failures of other key HIV/AIDS vaccine developers that utilized vaccine technologies quite different than those of GeoVax. FRB’s task will be to raise awareness of those significant differences. The media and investor information program as well as progress reports on GeoVax current and upcoming human trials will be conveyed on a regular basis. Media for the campaign may include print, television, radio and online information.
“We wanted to engage a firm that could effectively present the GeoVax story to current and prospective shareholders and to the media, while helping to educate the world about the crucial role that innovative vaccine technologies play in the fight against the global AIDS epidemic,” said Dr. Harriet Robinson, GeoVax co-founder/Chief Scientist.
“We look forward to being part of a team that will highlight GeoVax’s work in the frontline battle against HIV,” said FRB’s Kathy Waller. “FRB’s broad expertise in the biotech and healthcare industries will effectively convey the company’s vaccine development successes both to The Street and media communities.”
About GeoVax Labs, Inc. [www.geovax.com]
GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is covered by 20 issued or filed patent applications. GeoVax HIV/AIDS vaccines are designed to prevent development of Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, by vaccinating individuals prior to infection with the AIDS virus. In addition, GeoVax AIDS vaccines may be effective as therapeutics (treatment of people infected with AIDS virus). Studies evaluating these vaccines in already HIV/AIDS infected individuals are being planned.
GeoVax DNA and Recombinant MVA HIV/AIDS vaccines:
- Use DNA vaccines to “prime” immune responses and MVA vaccines to “boost” immune responses against the AIDS virus
- Express more than 50% of AIDS virus components in vaccinees and can not cause AIDS
- Protected 22 of 23 (96%) non-human primates against development of AIDS for over 3½ years
- Are manufactured & tested under GMP/GLP – EMEA (EU) and FDA guidelines
- Satisfactorily completed 2 earlier DNA & DNA/MVA -- HIV/AIDS vaccine Phase 1 human trials
- Are currently being tested in 3 Human Trials. One started in 2006, two in summer 2007
- Have been demonstrated safe to date in human trials
- Are demonstrating positive immune responses against HIV in the majority of vaccine recipients
- Are in planning stage for larger Phase 2 human trial in 2008
About Financial Relations Board
For more than 40 years, the Financial Relations Board has been one of the nation’s leaders for investor relations and financial communications. The firm offers a full array of services, including deep expertise in corporate positioning and communication, investment community targeting (market intelligence), financial media relations, shareholder management services, valuation analysis, and the company’s industry-leading Strategy Consulting Group. Financial Relations Board works alongside companies of all sizes, from established Fortune 100 brands to mid-size and micro-cap companies, pre-IPOs and the newly public. Headquartered in Chicago, the firm has full-service offices in New York, Los Angeles, San Francisco and Washington, D.C. Financial Relations Board is part of the Interpublic Group of Companies (NYSE: IPG). For more information on Financial Relations Board, visit www.frbir.com
Safe Harbor Statement: All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions on the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. Certain matters discussed in this news release are forward-looking statements involving certain risks and uncertainties including, without limitations, risks detailed in the Company’s Securities and Exchange Commission filings and reports.
###
Contact
Financial Relations Board
Melanie Nimrodi
3128533131
www.frbir.com
Melanie Nimrodi
3128533131
www.frbir.com
Contact
Categories